benlauhh
2021-08-31
Please like! Thank you!
See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate<blockquote>了解为什么AC Immune股票在阿尔茨海默病候选人数据公布后交易走高</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":818280687,"tweetId":"818280687","gmtCreate":1630413321349,"gmtModify":1631891743468,"author":{"id":3577336591268984,"idStr":"3577336591268984","authorId":3577336591268984,"authorIdStr":"3577336591268984","name":"benlauhh","avatar":"https://static.tigerbbs.com/3ee4a98f8cae9c1852df6f63da10a6ec","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like! Thank you! </p></body></html>","htmlText":"<html><head></head><body><p>Please like! Thank you! </p></body></html>","text":"Please like! Thank you!","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/818280687","repostId":1138801141,"repostType":4,"repost":{"id":"1138801141","kind":"news","pubTimestamp":1630412925,"share":"https://www.laohu8.com/m/news/1138801141?lang=zh_CN&edition=full","pubTime":"2021-08-31 20:28","market":"us","language":"en","title":"See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate<blockquote>了解为什么AC Immune股票在阿尔茨海默病候选人数据公布后交易走高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138801141","media":"Benzinga","summary":"AC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topl","content":"<p><div> AC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD). ...</p><p><blockquote><div>AC Immune SA及其合作伙伴基因泰克（罗氏控股公司的一部分）宣布了评估semorinemab治疗轻度至中度阿尔茨海默病（AD）的2期研究的主要数据。...</div></blockquote></p><p> <a href=\"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate\">网页链接</a> </div> </p><p><blockquote><a href=\"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate\">网页连接</a></blockquote></p><p></p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>See Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate<blockquote>了解为什么AC Immune股票在阿尔茨海默病候选人数据公布后交易走高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSee Why AC Immune Stock Is Trading Higher After Data From Alzheimer's Candidate<blockquote>了解为什么AC Immune股票在阿尔茨海默病候选人数据公布后交易走高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2021-08-31 20:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> AC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD). ...</p><p><blockquote><div>AC Immune SA及其合作伙伴基因泰克（罗氏控股公司的一部分）宣布了评估semorinemab治疗轻度至中度阿尔茨海默病（AD）的2期研究的主要数据。...</div></blockquote></p><p> <a href=\"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate\">网页链接</a> </div> </p><p><blockquote><a href=\"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate\">Benzinga</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ACIU":"AC Immune SA","RHHBY":"罗氏控股"},"source_url":"https://www.benzinga.com/general/biotech/21/08/22735879/see-why-ac-immune-stock-is-trading-higher-after-data-from-alzheimers-candidate","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138801141","content_text":"AC Immune SA and its collaborating partner Genentech, part of Roche Holdings AG, have announced topline data from Phase 2 study evaluating semorinemab in mild-to-moderate Alzheimer's disease (AD).\nSemorinemab met one of its co-primary endpoints, ADAS-Cog11 (cognitive scale). The second co-primary endpoint, ADCS-ADL (functional scale), was not met.\nSafety data showed that semorinemab was well tolerated with an acceptable safety profile and no unanticipated safety signals.\nSemorinemab demonstrated a statistically significant reduction in cognitive decline from baseline by 43.6% compared to placebo at week 49.\nThere was no effect on the other co-primary endpoint of reducing the rate of functional decline. Genentech has reported that the open-label portion of the study will continue as planned.\nFurther analyses are ongoing, and the company will submit topline data for presentation at the CTAD conference in November.\nSemorinemab is an investigational monoclonal anti-tau antibody that targets the N-terminal portion of the tau protein and is designed to bind to tau and slow its spread between neurons.\nPrice Action: ACIU shares are up 59.70% at $11.16 during the premarket session on the last check Tuesday.","news_type":1,"symbols_score_info":{"RHHBY":0.9,"ACIU":0.9}},"isVote":1,"tweetType":1,"viewCount":432,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/818280687"}
精彩评论